Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. While there are positive developments like the promising Phase II data for iopofosine and expanded partnerships, there are significant risks including financial sustainability concerns and regulatory approval uncertainties. The Q&A did not reveal any major concerns but highlighted the reliance on future milestones. The financials show decreased expenses but also a declining cash position. Without a clear market cap, the reaction is uncertain, but the mixed signals suggest a neutral impact on stock price.
Key Financial Performance
Cash and Cash Equivalents $8.3 million as of March 31, 2026, compared to $13.2 million at the end of 2025. The decrease is attributed to operational expenses.
Research and Development Expenses $3 million for Q1 2026, compared to $3.4 million for Q1 2025, a decrease due to reduced follow-up activities for the CLOVER WaM Phase IIb clinical study and preclinical product development, partially offset by increased manufacturing spend for iopofosine and CLR125.
General and Administrative Expenses $2.8 million for Q1 2026, compared to $3 million for Q1 2025, a modest decrease driven by reduced personnel costs.
Net Loss $5.7 million or $1.33 per share for Q1 2026, compared to $6.6 million or $4.30 per share for Q1 2025, reflecting reduced expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
iopofosine I 131: Reported positive 12-month follow-on data from the Phase IIb CLOVER WaM study for relapsed or refractory Waldenstrom Macroglobulinemia (WM). Achieved primary and secondary endpoints, showing durable and consistent responses in heavily pretreated WM populations. Plans to file for accelerated FDA approval and initiate a Phase III confirmatory trial.
CLR125: Initiated Phase Ib trial for relapsed/refractory triple-negative breast cancer (TNBC). The trial will evaluate three dose levels and dosing regimens, with endpoints including safety, tolerability, and preliminary efficacy measures.
WM treatment landscape: iopofosine I 131 is positioned to address a significant unmet need in WM, particularly for patients progressing after BTKi therapy. The WM patient population in the U.S. and EU is approximately 60,000 to 80,000.
Financing: Completed an oversubscribed financing of up to $140 million, including $35 million upfront and $105 million in milestone-based capital. This strengthens the balance sheet and supports the advancement of iopofosine and CLR125.
Financial performance: Ended Q1 2026 with $8.3 million in cash and cash equivalents. R&D expenses decreased to $3 million, and net loss reduced to $5.7 million compared to the previous year.
Regulatory strategy: Advancing plans for accelerated FDA approval for iopofosine I 131 and initiating a Phase III confirmatory trial.
Pipeline expansion: Progressing CLR125 for TNBC and planning further clinical trials to expand the radiopharmaceutical pipeline.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Risks: The company plans to file for accelerated FDA approval for iopofosine I 131 and initiate a Phase III confirmatory trial. However, meeting regulatory expectations and obtaining approval remains uncertain and poses a significant risk.
Financial Sustainability: While the company completed an oversubscribed financing of up to $140 million, its cash and cash equivalents were only $8.3 million as of March 31, 2026. The company is reliant on milestone-based funding, which depends on achieving specific development and regulatory milestones.
Clinical Trial Execution: The success of the Phase III confirmatory trial for iopofosine I 131 is critical. Delays or failures in trial execution could impact the company's ability to commercialize the drug and meet strategic objectives.
Market Competition: The company aims to position iopofosine as a foundational therapy for Waldenstrom Macroglobulinemia (WM). However, competition from existing and emerging therapies could limit market penetration and revenue potential.
Pipeline Development Risks: The company is advancing CLR125 for triple-negative breast cancer (TNBC), a challenging cancer subtype with limited treatment options. The success of this program is uncertain, and failure could impact the company's broader pipeline strategy.
Economic and Operational Risks: The company faces general economic uncertainties and operational challenges, including managing costs and maintaining focus on disciplined execution to achieve its milestones.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
FDA Accelerated Approval Filing: Cellectar plans to file for accelerated approval with the FDA for iopofosine I 131 based on positive 12-month follow-on data from the Phase IIb CLOVER WaM study.
Phase III Confirmatory Trial: The company will initiate a randomized Phase III confirmatory trial for iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) patients, with progression-free survival as the primary endpoint. The trial is expected to begin in late Q4 2026.
Financial Position and Funding: Cellectar completed an oversubscribed financing of up to $140 million, including $35 million upfront and $105 million in milestone-based capital. This funding will support the Phase III trial, potential commercialization of iopofosine, and the advancement of the CLR125 program.
CLR125 Phase Ib Trial: The company has initiated a Phase Ib trial for CLR125 in relapsed/refractory triple-negative breast cancer (TNBC). The trial will evaluate three dosing regimens and aims to determine safety, tolerability, and preliminary efficacy.
Market Opportunity for Iopofosine: Iopofosine is positioned to address a significant unmet need in WM, particularly for patients progressing after BTKi therapy. The company anticipates it could become a foundational therapy in the WM treatment landscape.
ASCO Conference Presentation: Cellectar will present subgroup analysis data from the CLOVER WaM trial at the upcoming ASCO conference, highlighting iopofosine's efficacy in post-BTKi settings.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Did most patients in the CLOVER WaM study go directly from a BTK inhibitor to the study drug, or did they receive other therapies in between?
A:Over 50% of patients in the study went directly from a BTK inhibitor to treatment with iopofosine. The other common transition was from rituximab, either as monotherapy or in combination with chemotherapy.
Q:What is the likely comparator arm for the Phase III program, and what is the expected progression-free survival (PFS) for the control arm population?
A:The comparator arm will be rituximab, cyclophosphamide, and dexamethasone (RCD). Historical data suggests PFS for the control arm population ranges from 5.8 months (refractory patients) to 8.1 months. For BTKi-refractory patients, PFS is approximately 5.8 months. In the Phase II CLOVER WaM study, iopofosine showed a PFS of over 15 months in the same patient population.
Q:How is the Phase III study powered, and what are the expectations for progression-free survival in the iopofosine arm?
A:The study is powered with 100 patients in each arm. The comparator arm assumes a PFS of 8 months, while the iopofosine arm assumes a PFS of no greater than 12 months. Based on CLOVER WaM data, the iopofosine arm is expected to achieve closer to 15 months of PFS, significantly outperforming the comparator arm.
Q:What is the potential timing for an NDA submission under accelerated approval for WM?
A:The study is planned to initiate at the end of this year, with patient enrollment taking 2-3 months. The new drug application (NDA) would then be submitted, and with the breakthrough designation, FDA action is expected within 6 months of submission. This places potential approval in the second half of 2027.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses provided sufficient detail and addressed the questions directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BTKi rituximab
BTKi setting
BTKi therapy
Chad
III trial
Ib trial
Phase III
Phase IIb
Phase Ib
TNBC
WM patient
capital
chemotherapy
cycle millicurie
development iopofosine
expectation
financing
funding
investor
iopofosine patient
label
median
meter cycle
millicurie meter
momentum
outcome
patient BTKi
patient CLOVER
patient Phase
patient WM
population date
population patient
receptor
strength
study iopofosine
study patient
subgroup
trial iopofosine
upfront
warrant milestone
CLRB Transcript
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call presents a mixed outlook. While there are positive developments like the promising Phase II data for iopofosine and expanded partnerships, there are significant risks including financial sustainability concerns and regulatory approval uncertainties. The Q&A did not reveal any major concerns but highlighted the reliance on future milestones. The financials show decreased expenses but also a declining cash position. Without a clear market cap, the reaction is uncertain, but the mixed signals suggest a neutral impact on stock price.
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call highlights strong interest in Phase III trials, potential partnerships, and a clear regulatory strategy for iopofosine I 131. Despite financial losses, the company has reduced expenses and extended its cash runway. The Q&A session reveals optimism about iopofosine's performance and market interest, with some uncertainties around data disclosure. Overall, the positive sentiment from partnerships and regulatory progress outweighs the financial concerns, suggesting a positive stock price movement.
Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed outlook. While there are positive developments such as decreased expenses and strong partnership momentum, significant risks persist, including reliance on rare isotopes and funding needs for trials. The Q&A reveals cautious optimism but lacks concrete guidance and pricing details, which may concern investors. Given the balanced nature of positive and negative factors, a neutral stock price reaction is expected.
Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript
Unknown8-14
While there are positive aspects, such as reduced R&D expenses and a strategic plan for accelerated approval, significant risks are present. Funding challenges and regulatory uncertainties are major concerns, as the company's plans hinge on securing additional capital. The Q&A reveals management's lack of clarity on critical timelines, further increasing uncertainty. The decrease in cash reserves and increased net loss also contribute to a negative outlook. Without a market cap, we assume mid-cap, leading to a likely stock price decrease of -2% to -8%.
CLRB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
